<html><head><link rel="stylesheet" type="text/css" href="usc.css"/><title>U.S.C. Title 21 - FOOD AND DRUGS</title></head><body>
<span style="font-weight:bold;font-size:12pt;">21 U.S.C. </span><br/>
<span style="font-size:10pt">United States Code, 2009 Edition</span><br/>
<span style="font-size:10pt">Title 21 - FOOD AND DRUGS</span><br/>
<span style="font-size:10pt">CHAPTER 9 - FEDERAL FOOD, DRUG, AND COSMETIC ACT</span><br/>
<span style="font-size:10pt">SUBCHAPTER X - MISCELLANEOUS</span><br/>
<span style="font-size:10pt">Sec. 393a - Office of Pediatric Therapeutics</span><br/>
<span style="font-size:10pt">From the U.S. Government Printing Office, <a href="http://www.gpo.gov">www.gpo.gov</a></span><br/><br/>
<!-- documentid:21_393a  usckey:210000000039300000000000a00000000 currentthrough:20100201 documentPDFPage:411 -->
<!-- itempath:/210/CHAPTER 9/SUBCHAPTER X/Sec. 393a -->
<!-- itemsortkey:210AAMR -->
<!-- expcite:TITLE 21-FOOD AND DRUGS!@!CHAPTER 9-FEDERAL FOOD, DRUG, AND COSMETIC ACT!@!SUBCHAPTER X-MISCELLANEOUS!@!Sec. 393a -->
<!-- field-start:head -->
<h3 class="section-head">&sect;393a. Office of Pediatric Therapeutics</h3>
<!-- field-end:head -->
<!-- field-start:statute -->
<h4 class="subsection-head">(a) Establishment</h4>
<p class="statutory-body">The Secretary of Health and Human Services shall establish an Office of Pediatric Therapeutics within the Food and Drug Administration.</p>
<h4 class="subsection-head">(b) Duties</h4>
<p class="statutory-body">The Office of Pediatric Therapeutics shall be responsible for coordination and facilitation of all activities of the Food and Drug Administration that may have any effect on a pediatric population or the practice of pediatrics or may in any other way involve pediatric issues, including increasing pediatric access to medical devices.</p>
<h4 class="subsection-head">(c) Staff</h4>
<p class="statutory-body">The staff of the Office of Pediatric Therapeutics shall coordinate with employees of the Department of Health and Human Services who exercise responsibilities relating to pediatric therapeutics and shall include&mdash;</p>
<p class="statutory-body-1em">(1) one or more additional individuals with expertise concerning ethical issues presented by the conduct of clinical research in the pediatric population; and</p>
<p class="statutory-body-1em">(2) one or more additional individuals with expertise in pediatrics as may be necessary to perform the activities described in subsection (b) of this section.</p>
<!-- field-end:statute -->
<!-- field-start:sourcecredit -->
<p class="source-credit">(Pub. L. 107&ndash;109, &sect;6, Jan. 4, 2002, 115 Stat. 1414; Pub. L. 110&ndash;85, title III, &sect;306(a), Sept. 27, 2007, 121 Stat. 864.)</p>
<!-- field-end:sourcecredit -->
<!-- field-start:notes -->
<!-- field-start:codification-note -->
<h4 class="note-head">Codification</h4>
<p class="note-body">Section was enacted as part of the Best Pharmaceuticals for Children Act, and not as part of the Federal Food, Drug, and Cosmetic Act which comprises this chapter.</p>
<!-- field-end:codification-note -->
<!-- field-start:amendment-note -->
<h4 class="note-head">Amendments</h4>
<p class="note-body">2007&mdash;Subsec. (b). Pub. L. 110&ndash;85 inserted &ldquo;,&nbsp;including increasing pediatric access to medical devices&rdquo; before period at end.</p>
<!-- field-end:amendment-note -->
<!-- field-end:notes -->


</body></html>